Sign in
GNRRF Stock Price, Chart, Stats & News
GeNeuro S.A.
Save
GeNeuro S.A. (GNRRF) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
GNRRF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
GeNeuro SA is a clinical-stage biopharmaceutical company focused on discovering and advancing therapies for neurodegenerative and autoimmune disorders. Its flagship therapeutic, temelimab, a monoclonal antibody, has successfully completed a Phase IIb clinical trial for multiple sclerosis. This same antibody is currently undergoing Phase IIa studies for type 1 diabetes and has entered Phase I trials for chronic inflammatory demyelinating polyneuropathy.
Similar securities
Based on sector and market capitalization
Report issue